In this issue:
New Australian National Lung Screening program rolling out in 2025
Lung cancer scorecard 2023
ESMO Clinical Practice Guidelines for oncogene-addicted metastatic NSCLC
Updates to NCCN Clinical Practice Guidelines
Durable survival benefit to cemiplimab vs chemo in PD-L1- high NSCLC
IPSOS: atezolizumab monotherapy advantageous in NSCLC ineligible for chemo doublet
PBAC recommendations
TGA registrations
PBS listing
World first approval of subcutaneous atezolizumab
12th World Lung Cancer Day observed
TROPION-Lung02: Datopotamab deruxtecan doublet & triplet combos have activity in NSCLC
Pyrotinib promising for advanced HER2-mutant NSCLC
COVID-19 resources
Conferences & Workshops
Please login below to download this issue (PDF)